GRAIL completed over 174,000 Galleri tests during nine months of 2026.
Third-quarter Galleri test volumes increased 24% over the prior year.
Management expects a final FDA approval decision by early 2027.
On its third-quarter 2026 earnings call, held on Nov. 4, 2026, GRAIL (NASDAQ:GRAL) highlighted a positive Food and Drug Administration (FDA) advisory committee vote for its Galleri multi-cancer early detection (MCED) test. FDA premarket approval (PMA), the agency's review process for high-risk medical devices, would create a distinct market class for Galleri.
It'd establish the test as the only approved screening tool that detects dozens of cancer types from one blood draw. Three things management said on the earnings call stand out for long-term investors.
An expert panel backed Galleri through the PMA review pathway in September. That vote positions the test to become the first FDA-approved multi-cancer screening tool. Management expects a final decision early in the first quarter of 2027, which would allow GRAIL to differentiate its product from unapproved competitors.
Galleri is the first multi-cancer early detection test to undergo FDA review through the PMA pathway, and we were very pleased with the positive vote.
-- Josh Ofman, Chief Executive Officer
GRAIL introduced a promotional price in September to lower cost barriers in the self-pay market. That promotion pushed average selling price down to roughly $660 per test. Management is deliberately accepting lower gross margins today to expand provider adoption, build repeat testing habits, and prepare for insurance coverage.
We are intentionally prioritizing growth and market penetration over margin optimization in the short term to drive market momentum as we approach an FDA decision and other meaningful milestones.
-- Aaron Freidin, Chief Financial Officer
Higher lab volumes should lower cost of goods sold (COGS) by about $100 per unit. That cost reduction helps offset a legacy royalty payment to Illumina that resumes in late December 2026. Management targets long-term adjusted gross margins of 50% to 60% as unit processing costs drop toward $230 at scale.
From where we are today, we see approximately $100 decrease in COGS due to scale as we approach our COGS of about $230, including the royalty.
-- Aaron Freidin, Chief Financial Officer
Commercial momentum's building across provider channels and electronic health record integrations. GRAIL's leaning on its clinical data set to secure coverage with private insurers and government payers.
We expect to further increase investment in brand awareness and competitive differentiation going forward as we reshape the market. If we obtain FDA approval, we will clearly differentiate Galleri as a robust, well-validated FDA-approved test.
-- Josh Ofman, Chief Executive Officer
A cash balance of $788.7 million provides financial runway into 2029 while GRAIL expands marketing and sales coverage. Management's aligning capital deployment to build repeat testing demand once insurance reimbursement opens.
We are continuing to invest to capture a long-term market where regular annual testing is available and reimbursed.
-- Josh Ofman, Chief Executive Officer
Before you buy stock in Grail, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Grail wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*
Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 19, 2026.
The Motley Fool recommends Grail. The Motley Fool has a disclosure policy.